Patents by Inventor Julie Sneddon

Julie Sneddon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bone morphogenetic protein antagonist and uses thereof
    Patent number: 8383349
    Abstract: The present invention relates to the use of proteins that are differentially expressed in tumor associated stromal cells, as compared to normal stromal, as biomolecular targets for tumor treatment therapies. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: February 26, 2013
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Hanson Zhen, Julie Sneddon, Patrick O. Brown, Anthony Oro
  • Gene expression signature for prediction of human cancer progression
    Patent number: 7943306
    Abstract: Methods are provided for classification of cancers by the expression of a set of genes referred to as the core serum response (CSR), or a subset thereof. The expression pattern of the CSR in normal tissues correlates with that seen in quiescent fibroblasts cultured in the absence of serum, while cancer tissues can be classified as having a quiescent or induced CSR signature. Patients with the induced CSR signature have a higher probability of metastasis. Classification according to CSR signature allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like.
    Type: Grant
    Filed: January 12, 2006
    Date of Patent: May 17, 2011
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Howard Yuan-Hao Chang, Julie Sneddon, Patrick O. Brown
  • Bone morphogenetic protein antagonist and uses thereof
    Publication number: 20090041757
    Abstract: The present invention relates to the use of proteins that are differentially expressed in tumor associated stromal cells, as compared to normal stromal, as biomolecular targets for tumor treatment therapies. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention.
    Type: Application
    Filed: March 13, 2008
    Publication date: February 12, 2009
    Inventors: Hanson Zhen, Julie Sneddon, Patrick O. Brown, Anthony Oro
  • Gene expression signature for prediction of human cancer progression
    Publication number: 20060183141
    Abstract: Methods are provided for classification of cancers by the expression of a set of genes referred to as the core serum response (CSR), or a subset thereof. The expression pattern of the CSR in normal tissues correlates with that seen in quiescent fibroblasts cultured in the absence of serum, while cancer tissues can be classified as having a quiescent or induced CSR signature. Patients with the induced CSR signature have a higher probability of metastasis. Classification according to CSR signature allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like.
    Type: Application
    Filed: January 12, 2006
    Publication date: August 17, 2006
    Inventors: Howard Chang, Julie Sneddon, Patrick Brown